Combining Lomustine with Reirradiation for Glioblastoma Progression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of combining lomustine, a standard chemotherapy drug, with reirradiation in patients experiencing the first progression of glioblastoma after initial treatment. The study aims to determine if this combination leads to improved overall survival compared to lomustine alone. Patients eligible for the trial must have measurable disease and a confirmed diagnosis of glioblastoma, with treatment starting at least six months after prior radiotherapy. The trial is randomized and phase III, indicating a robust methodology to assess the treatment's efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Before patient's enrolment, written informed consent must be given according to ICH/GCP, and national/local regulations.
* Patients with first progression or recurrent glioblastoma after standard chemoradiotherapy (any treatment other than use of nitroureas) having occurred at least 6 months after the end of prior radiotherapy
* Measurable disease according to RANO criteria with a maximum tumour diameter of 5 cm (local investigator assessment)
* In case of surgery for recurrence: fully recovered from surgery, confirmation of recurrence by histology, and patient fit for treatment as per local investigator assessment.
* Histologically proven diagnosis of glioblastoma, IDH wildtype per WHO 2021 classification and local assessment of tissue from diagnosis or recurrence
* Initial treatment of newly diagnosed glioblastoma by maximal safe resection and postsurgical concurrent conventionally fractionated or abbreviated (minimum 15 fractions) chemoradiotherapy with or without maintenance chemotherapy with temozolomide (patient must have received at least one dose)
* Stable or decreasing dose of steroids for 7 days prior to enrolment
* Age ≥ 18 years
* WHO Performance status of 0-2
* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment.
* Patients of childbearing / reproductive potential must agree to use adequate birth control measures during the study treatment period and for at least 6 months after the last dose of study treatment. A highly effective method of birth control is defined as a method which results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly.
* Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.
* Non-sterile males must use contraception during treatment and for 6 months after the last dose.
* Non-sterile males must avoid sperm donation for the duration of the study and for at least 6 months after the last dose of study treatment.

Exclusion Criteria:

* Any prior anticancer treatment for recurrent glioblastoma (except surgery)
* Significant reduction in thrombocyte and/or leukocyte counts as well as severe renal impairment according to investigator's opinion
* History or present acute leukaemia or any myeloid disease
* Known hypersensitivity to the active components or excipients of lomustine
* Known coeliac disease or wheat allergy
* Live attenuated vaccine in the 3 months prior to lomustine initiation
* Any serious or uncontrolled medical condition (e.g., infections, chronic alcoholism, drug addiction) or abnormality, in the judgment of the investigator that prohibits obtaining informed consent, safe participation and study completion
* Known contraindication to imaging tracer or any product of contrast media and Magnetic Resonance Imaging (MRI) contraindications
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the trial.

Where it's running

• A.O Landeskrankenhaus - Innsbruck Universitaetsklinik
  Innsbruck, Austria Recruiting
• Kepler University Hospital - Neuromed campus
  Linz, Austria Recruiting
• Universitaetsklinikum Wien - AKH unikliniken
  Vienna, Austria Recruiting
• Azorg
  Aalst, Belgium Recruiting
• Cliniques Universitaires Saint-Luc
  Brussels, Belgium Recruiting
• Universitair Ziekenhuis Gent
  Ghent, Belgium Recruiting

Study contacts

• Principal investigator: Matthias Preusser, Prof. — EORTC Study Coordinator
• Study coordinator: Eortc
• Email: eortc@eortc.org
• Phone: +3227741611

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radiotherapy for BCG-Unresponsive Bladder CIS

  This study tests whether radiation therapy can help people with BCG-unresponsive non-muscle-invasive bladder cancer to delay or avoid bladder removal.

  Recruiting at 3 sites European Organisation for Research and Treatment of Cancer - EORTC · Anderlecht, Brussels Capital and 2 other locations · NCT06990061

• Vorasidenib as daily maintenance therapy for adults with IDH‑mutant grade 2–3 astrocytoma

  This trial will test whether taking daily vorasidenib after chemoradiotherapy delays tumor progression compared with placebo in adults with IDH‑mutant grade 2 or 3 astrocytoma.

  Recruiting at 35 sites Phase 3 European Organisation for Research and Treatment of Cancer - EORTC · Bedford Park and 58 other locations · NCT06809322

• Radiopharmaceutical treatment for advanced kidney cancer using 177Lu-PSMA-617

  This study tests whether 177Lu-PSMA-617 can help adults with metastatic clear cell renal cell carcinoma that has progressed after immunotherapy and a VEGFR-TKI.

  Recruiting at 2 sites Phase 2 European Organisation for Research and Treatment of Cancer - EORTC · Caen and 1 other locations · NCT06783348

• Single‑fraction versus multiple‑fraction SBRT for treating limited metastases (SPRINT)

  This trial will test whether a single high‑dose SBRT treatment works as safely and effectively as multiple smaller SBRT treatments for people with limited metastases from breast, prostate, lung, or colorectal cancer.

  Recruiting at 2 sites European Organisation for Research and Treatment of Cancer - EORTC · Aalst and 14 other locations · NCT06462963

• Using 177Lu-DOTATATE to treat recurrent meningioma

  This study is testing if a new targeted treatment called 177Lu-DOTATATE can help people with recurrent meningioma who haven't had success with regular treatments like surgery and radiation.

  Recruiting at 17 sites Phase 2 European Organisation for Research and Treatment of Cancer - EORTC · Innsbruck and 18 other locations · NCT06326190

• Using Tebentafusp to prevent recurrence in high-risk ocular melanoma patients

  This study is testing if a new treatment called tebentafusp can help prevent the return of high-risk uveal melanoma in patients after their initial treatment.

  Recruiting at 15 sites Phase 3 European Organisation for Research and Treatment of Cancer - EORTC · Lake Success, New York and 14 other locations · NCT06246149

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.